Please login to the form below

Not currently logged in
Email:
Password:

MedImmune appoints Dr Anand Subramony

He joins from Novartis to take up drug delivery and device development role

AstraZeneca AZ MedImmune Anand SubramonyAstraZeneca's MedImmune unit has appointed Dr Anand Subramony as its new vice president of drug delivery and device development.

He joins the company's biopharmaceutical development unit from Novartis, whose Institutes for Biomedical Research he previously worked for in Cambridge, Massachusetts.

While at Novartis Dr Subramony established and headed company's novel delivery technologies and therapeutics group.

Prior to that he held leadership positions at Dr. Reddy's Laboratories in Bridgewater, New Jersey and Johnson & Johnson/Alza Corporation in Mountain View, California.

Dr Subramony will bring to MedImmune experience that includes drug-device combination products and a further boost to its focus on biologics delivery and device development.

13th March 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mednet Group

PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...